5-Oct-2024 5:27 AM CST - Yahoo Finance Editas Medicine Secures $57M Deal for Gene-Editing Technology Editas Medicine ( (EDIT) ) has issued an update. Editas Medicine, Inc. struck a deal on October 3, 2024, with a subsidiary of DRI Healthcare Trust, selling future license fees and payments from Vertex Pharmaceuticals for $57 million.
4-Oct-2024 9:05 PM CST - GlobalData Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream from Vertex Pharmaceuticals to a subsidiary of DRI Healthcare in return for an immediate $57m cash boost.
3-Oct-2024 5:42 PM CST - Business Insider Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million.
19-Sep-2024 5:45 AM CST - Business Insider Editas Medicine (EDIT) Receives a Hold from RBC Capital In a report released today, Luca Issi from RBC Capital maintained a Hold rating on Editas Medicine (EDIT - Research Report), with a price
28-Aug-2024 8:00 AM CST - Yahoo Finance Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs,
15-Aug-2024 5:41 AM CST - Yahoo Finance We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate Since it has a market capitalisation of US$308m, Editas Medicine's US$172m in cash burn equates to about 56% of its market value. That's high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution).
5-Oct-2024 5:27 AM CST - Yahoo Finance Editas Medicine Secures $57M Deal for Gene-Editing Technology Editas Medicine ( (EDIT) ) has issued an update. Editas Medicine, Inc. struck a deal on October 3, 2024, with a subsidiary of DRI Healthcare Trust, selling future license fees and payments from Vertex Pharmaceuticals for $57 million.
4-Oct-2024 9:05 PM CST - GlobalData Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream from Vertex Pharmaceuticals to a subsidiary of DRI Healthcare in return for an immediate $57m cash boost.
3-Oct-2024 5:42 PM CST - Business Insider Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million.
19-Sep-2024 5:45 AM CST - Business Insider Editas Medicine (EDIT) Receives a Hold from RBC Capital In a report released today, Luca Issi from RBC Capital maintained a Hold rating on Editas Medicine (EDIT - Research Report), with a price
28-Aug-2024 8:00 AM CST - Yahoo Finance Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs,
15-Aug-2024 5:41 AM CST - Yahoo Finance We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate Since it has a market capitalisation of US$308m, Editas Medicine's US$172m in cash burn equates to about 56% of its market value. That's high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution).
